First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors
Titel:
First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors
Auteur:
Bang, Y.J. Giaccone, G. Im, S.A. Oh, D.Y. Bauer, T.M. Nordstrom, J.L. Li, H. Chichili, G.R. Moore, P.A. Hong, S. Stewart, S.J. Baughman, J.E. Lechleider, R.J. Burris, H.A.